T2 - Translation to Patients - Introduction (9:18)

Loading...

Из курса от партнера University of Rochester

Introduction to Translational Science

12 оценок

University of Rochester

Introduction to Translational Science

12 оценок

Translational science seeks to speed up the process of moving research discoveries from the laboratory into healthcare practices. Numerous scientific and organizational roadblocks can act as obstacles along the path of translation and ultimately hinder the speed of progress in medical research. The National Center for Advancing Translational Sciences (NCATS) was established by the National Institutes of Health (NIH) to transform and accelerate the translational research process, with the intended result of getting treatments to more patients faster. The field of Translational Science aims to bridge these gaps by: Developing new approaches, technologies, resources and models Demonstrating the usefulness of new approaches, technologies, resources and models Disseminating the resulting data, analyses, and methodologies to the broad scientific community Introduction to Translational Science is an introductory course that provides students with a broad understanding of translational science, the types of research that are conducted under the translational science umbrella, and how this research impacts the public at large.The course will compare and contrast current impediments to clinical research with the potential of translational science and will include selected case studies from the University of Rochester.

Из урока

T2 - Translation to Patients and T3 - Translation to Practice

The third lesson in Introduction to Translational Science provides an introduction to T2 research, which is research that translates findings from T1 research (humans) to patients. T2 research is often conducted through Phase III clinical trials, observational studies, evidence synthesis, and clinical guidelines development. The fourth lesson in Introduction to Translational Science provides an introduction to T3 research, which is research that translates findings from T2 research (patients) to actual clinical practices. T3 research is often conducted through Phase IV clinical trials, health services research, and clinical outcomes research.

T2 - Translation to Patients - Introduction (9:18)9:18

T2 - Translation to Patients - Part I (7:34)7:33

T2 - Translation to Patients - Part II (6:50)6:50

T2 - Translation to Patients - Part III (6:50)6:50

T2 - Translation to Patients - Part IV (9:55)9:55

Познакомьтесь с преподавателями

Martin S. Zand, MD, PhD
Professor of Medicine – Nephrology
School of Medicine

[MUSIC]

Welcome back to Introduction to Translational Science.

This is segment three, Translation to Patients.

In this segment, you're going to hear about the amazing work of Dr.

Raymond Dorsey and Dr. Marvin Doyley,

both translational scientists at the University of Rochester Medical Center.

Dr. Doyley studies imaging and new ways to look at the human body.

Dr. Dorsey studies new ways to perform translational research

in patients with neurologic diseases and how to use technology.

Really cool, Dr. Dorsey on my phone, an app that he invented.

In this segment, we're going to talk about T2 Research, Translation to Patients.

At this level of research, investigators test new interventions under

controlled environments to figure out is this care effective.

Findings from T2 studies yield knowledge about the efficacy of the interventions,

and form the basis of clinical application.

Taking these treatments in to the clinic outside of controlled studies.

These types of studies involve asking the question,

does this treatment really benefit patients?

We're no longer about discovery,

we're at the phase of trying to figure out implementation.

T2 study designs include phase III clinical trials, observational studies,

evidence synthesis-based studies, and development of guidelines.

Let's dive a little deeper into this process of translation.

In the last segment, we spoke about basic research and

translation into humans, the T0, T1 transition.

In this segment we're going to talk about translation

from T1 now into T2, Translation to Patients.

Phase III Clinical Trials are an integral part of translation to patients.

They start with a new treatment that's already passed the phase I and

phase II clinical trials level, and

they move into testing in a larger group of individuals.

The goal of these trials is to really dig in and

find out if the new treatment is better than a standard treatment.

Or if a standard treatment does not exist, if the new treatment really confers

an advantage, does it improve the health of the person receiving that treatment.

These trials are bigger, they usually include a large number of patients, 300 or

more, sometimes a few thousand patients, and they take a number of years to finish.

Not every discovery makes it to a phase III clinical trial,

and thus the discoveries that do make it to these trials

show even greater promise for efficacy and for

providing new therapies, diagnostic methods, and treatments.

The next type of study is observational.

Observational studies focus on the causes, preventions, and treatments for a disease.

They also may differ from experimental design studies

because the investigator only observes the subjects,

they don't really intervene, except to gather data.

So subjects in observational studies are not receiving active therapies.

Observational studies can be used to develop diagnostic methods,

to study the progression of certain medical conditions or diseases.

To look retrospectively and observe subjects and occurrences that have

already happened in the past, and use that data in records and

self-reports to make new observations into advanced knowledge.

Observational studies designs can look at a group of people, a cohort.

They can be case-controlled where they look at individuals

across a time spectrum.

They can look at a cross-section of an entire group of people at

specific time points.

And they can look at an entire population, an ecology, and

look at how those individuals are interacting with their environment.

And examine the relationship between, for example,

exposure to a toxic environment and

an outcome by looking at how the population responds at

the level of data rather than the level of an individual.

The next type of study is called an Evidence Synthesis study.

These studies look at the entire magnitude of evidence,

perhaps across a variety of smaller studies.

And they use advanced statistical techniques to synthesize that

knowledge and to ask okay, now that we've done a dozen different

studies on this therapy, what do all those studies combined show?

The collection of studies is often as effective or more effective than a much,

much larger controlled studies that might only apply to a small number of people.

A type of these studies is called a meta-analysis.

And this study design uses statistical methods to combine study

findings across a number of different studies.

And really, the ultimate goal of a meta-analysis is to look at how strong is

the effect of a therapy, or how accurate is a diagnosis.

A different type of study is a synthesis of evidence from systemic reviews.

This type of study design looks at a set of clearly specified,

and rigorous, and reproducible methods, and

looks to analyze the results from all the relevant studies on a topic.

The goal of a systemic review is to identify what is known and

not known about a selected topic.

It's to look at the gaps in our knowledge and to figure out where to go next.

Finally, a clinical guidelines development study looks to

develop guidelines that translate best evidence into best practice.

Of course, when we go to our health care providers, we want them to be

acting on the latest guidelines and provide us with the best care.

Those guidelines have to be developed somewhere.

Good clinical guidelines promote quality,

they reduce variations in how health care is delivered.

They improve diagnostic accuracy and they discourage the use of ineffective, or

even interventions that we have found to be potentially harmful.

The steps in developing these guidelines include identifying and

refining the subject area, getting together a group of experts and

other practitioners to wait the evidence.

And then to develop and translate that into recommendations

that can be adopted as a clinical practice guideline for all practitioners to use.

External review of the guideline is usually the last step.

So in the next segment, you're going to hear first from Dr.

Ray Dorsey from the University of Rochester Center for

Human and Experimental Therapeutics.

And I'm not going to steal Dr. Dorsey's really cool app and

research details, I'll let you hear from him.

He's changing the way scientific his research is done.

It used to be that you had to go to the research center, to be a research subject.

Dr. Dorsey's goal is that the research center comes to you.

And then you're going to hear from Dr. Marvin Doyley,

who's associate professor of Electrical and Computer Engineering and

Biomedical Engineering at the University of Rochester.

Dr. Doyley is helping us imagine new ways of looking at the human body and

imaging to allow us to see things that we never were able to see before.

I hope you enjoy this vision of our research future and translation.

[MUSIC]

Ознакомьтесь с нашим каталогом

Присоединяйтесь бесплатно и получайте персонализированные рекомендации, обновления и предложения.

Coursera делает лучшее в мире образование доступным каждому, предлагая онлайн-курсы от ведущих университетов и организаций.

© Coursera Inc., 2018 Все права защищены.

Загрузить из App Store

Загрузить в Google Play